Chronic SGLT2 inhibitor treatment may thereby improve ventricular conduction and diminish arrhythmia vulnerability in human patients affected with DMD and other arrhythmia disorders associated with reduced peak INa. The gene discussed is SLC5A2; the disease is Duchenne muscular dystrophy.